The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The India generic injectables market reached a value of US$ 2.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2027, exhibiting a CAGR of 12.8% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic injectables refer to alternative drugs that are bio-equivalent of their branded counterparts in terms of active ingredients, strength, quality, effectiveness, intended use, and dosage. They are used to treat various life-threatening and chronic diseases, such as cancer, diabetes, rheumatoid arthritis, cardiovascular ailments, and respiratory infections. As compared to innovator drugs, generic injectables offer maximized patient compliance, reduced frequency of drug delivery, limited price erosion, and higher profitability for manufacturers.
The increasing prevalence of chronic diseases in India, due to the rising pollution levels and unhealthy lifestyle of the population are the major factors driving the generic injectables market growth. This, in turn, has led to a rise in the expenditure on innovation in generic injectables for effective drug administration and faster recovery of patients. Additionally, an expansion in the life science industry and rapid technological advancements in drug delivery systems, such as the development of self-injection devices, are contributing to the market growth. Moreover, rising economic development in India has resulted in improved healthcare facilities, which is acting as another growth-inducing factor. Apart from this, the increasing shortage of branded medicines and expiry of patents of branded items, are further creating a positive outlook for the market in the country.
IMARC Group provides an analysis of the key trends in each sub-segment of the India generic injectables market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on therapeutic area, container and distribution channel.
Breakup by Therapeutic Area:
Breakup by Container:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Therapeutic Area, Container, Distribution Channel, Region|
|Region Covered||North India, West and Central India, South India, East India|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 2999
Corporate License: US$ 3499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at